Trial · NCT06176989
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
NCT06176989, Phase 2, Recruiting, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors. Trials, record NCT06176989. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06176989
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
- NCT number
- NCT06176989
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma, Metastatic Large-cell Neuroendocrine Carcinoma, Locally Advanced Large-cell Neuroendocrine Carcinoma, Metastatic Olfactory Neuroblastoma, Locally Advanced Olfactory Neuroblastoma, Metastatic Sinonasal Undifferentiated Carcinoma, Locally Advanced Sinonasal Undifferentiated Carcinoma
- Interventions
- Enasidenib
- First posted
- 2023-12-20
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) in all study participants | up to 5 years post study treatment | The date of first treatment until the date of disease progression or death without progression |
| Secondary | safety | from study treatment initiation up to 28 days post study treatment | Adverse events assessed per CTCAE version 5 |
| Secondary | clinical benefit rate (CBR: CR+PR+SD>4 months) in participants with IDH2m SNUC | up to 5 years post study treatment | Fraction of participants experiencing CBR = CR+PR+ SD \> 16 weeks |
| Secondary | PFS in non-SNUC IDH2m tumors | up to 5 years post study treatment | The date of first treatment until the date of disease progression or death without progression |
| Secondary | Overall survival (OS) in non-SNUC IDH2m tumors | up to 5 years post study treatment | The date of first treatment until date of death or last follow-up |
| Secondary | clinical benefit rate (CBR: CR+PR+SD>4 months) in participants with non-SNUC IDH2m tumors | up to 5 years post study treatment | Fraction of participants experiencing CBR = CR+PR+ SD \> 16 weeks |
| Secondary | Overall survival (OS) in participants with IDH2m SNUC | up to 5 years post study treatment | The date of first treatment until date of death or last follow-up |
| Secondary | PFS in participants with IDH2m SNUC | up to 5 years post study treatment | The date of first treatment until the date of disease progression or death without progression |
| Secondary | Correlate UGTIA1 genotypes with toxicity | from study treatment initiation up to 28 days post study treatment | Descriptive statistics of AE occurence per UGTIA1 genotype |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06176989
GET https://conductscience.org/api/trials/v1/NCT06176989/registered